NMPA Grants Simultaneous Dual Approval for HutchMed’s SYVIK (Sovleplenib) – First Oral Syk Inhibitor for ITP and wAIHA in China

Fineline Cube
5 Min Read
Summarize with AI

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that China’s National Medical Products Administration (NMPA) has granted simultaneous approval for two New Drug Applications (NDAs) of SYVIK (sovleplenib), a novel, highly selective oral spleen tyrosine kinase (Syk) inhibitor, in chronic primary immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (wAIHA) — two autoimmune cytopenias with substantial unmet need after failure of prior therapy.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyNational Medical Products Administration (NMPA), China
Approval TypeSimultaneous approval of two New Drug Applications (NDAs)
ProductSYVIK (sovleplenib) – novel, highly selective oral Syk inhibitor
Indication 1Adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy
Indication 2Adult patients with wAIHA who have had an insufficient response to prior corticosteroid therapy
Approval Date19 November 2026
Supporting TrialsESLIM‑01 (Phase III, ITP) and ESLIM‑02 (Phase II/III, wAIHA)

Drug Profile & Mechanism of Action

  • Molecule: Sovleplenib, a novel, highly selective oral spleen tyrosine kinase (Syk) inhibitor.
  • Mechanism: Syk signaling drives Fc‑gamma receptor–mediated destruction of antibody‑coated blood cells; selective Syk inhibition targets the underlying mechanism of both platelet destruction in ITP and red‑cell hemolysis in wAIHA.
  • Administration: Oral therapy, offering a convenience advantage over infusion‑ or injection‑based options in autoimmune cytopenias.
  • Dual‑Indication Strategy: A single platform approved simultaneously in two distinct autoimmune blood disorders — validating the Syk mechanism across Fc‑mediated cytopenias.

Clinical Evidence – ITP (ESLIM‑01, Phase III)

EndpointSovleplenibPlaceboStatistical Significance
Durable Response Rate48.4 %0 %p < 0.0001
SafetyTolerable safety profile––
Quality of LifeDemonstrated improvement––

ESLIM‑01 (NCT05029635) was a randomized, double‑blind, placebo‑controlled Phase III trial conducted in 188 adult patients in China with primary ITP who had received at least one prior line of standard therapy. Sovleplenib demonstrated a clinically meaningful early and sustained durable platelet response, with a durable response rate of 48.4 % versus zero with placebo (p < 0.0001), alongside a tolerable safety profile and improvement in quality of life.

Clinical Evidence – wAIHA (ESLIM‑02, Phase II/III)

Endpoint (Weeks 5–24)SovleplenibPlaceboStatistical Significance
Durable Response Rate66 %15 %p < 0.0001
SafetyFavorable profile; no treatment‑related deaths or discontinuations––

ESLIM‑02 (NCT05535933) was a randomized, double‑blind, placebo‑controlled Phase II/III trial in China in adult patients with primary or secondary wAIHA who had relapsed or were refractory to prior glucocorticoid treatment. During weeks 5–24, the durable response rate in the sovleplenib group was significantly higher than in the placebo group (66 % vs 15 %, p < 0.0001), with a favorable safety profile and no treatment‑related deaths or discontinuations reported.

Market Impact & Outlook

  • Autoimmune Cytopenia Landscape: Chronic ITP and wAIHA are debilitating autoimmune blood disorders in which patients frequently relapse after, or respond insufficiently to, corticosteroids and other standard therapies — leaving a large population with limited options.
  • First‑in‑Class Positioning: SYVIK’s simultaneous dual NDA approval establishes sovleplenib as a highly selective oral Syk inhibitor addressing two Fc‑mediated cytopenias under a single regulatory event in China.
  • Evidence Base: Head‑to‑head placebo‑controlled pivotal data — 48.4 % vs 0 % durable response in ITP and 66 % vs 15 % in wAIHA, both at p < 0.0001 — provide a robust foundation for guideline uptake and market access negotiations.
  • Commercial Next Steps: Launch and market‑access execution in China by HutchMed; pricing, reimbursement status and launch timeline were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market access, pricing and clinical expansion of SYVIK (sovleplenib) in China. Actual results may differ materially due to risks inherent in commercial launch, reimbursement negotiations, competitive dynamics and regulatory developments.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *